NCT00518323 - A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Schizophrenia

Interventions

DRUG

Paliperidone ER

3 mg or 6 mg tablet once daily for 6 weeks

DRUG

Placebo

Once daily for 6 weeks

DRUG

Paliperidone ER

1.5 mg tablet once daily for 6 weeks

DRUG

Paliperidone ER

6 mg or 12 mg tablet once daily for 6 weeks

Trial Locations (34)

Unknown

Cerritos

Fountain Valley

San Diego

Santa Ana

Washington D.C.

Lake Charles

Boston

Cleveland

Portsmouth

Spokane

Bangalore

Chennai

Hyderabad

Hyderabad Andra Pradesh

Mangalore

New Delhi

Varanasi

Bucharest

Ekaterinburg Na

Kazan'

Moscow

Moscow Russia

Nizhny Novgorod

Saint Petersburg

Saratov

Smolensk Region N/A

Stavropol Na

Tomsk Na

Yaroslavl

Hlevakha

Kharkiv

Kiev

Odesa

Simferopol

All Listed Sponsors

lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY